```
=> d his

     (FILE 'HOME' ENTERED AT 14:06:01 ON 06 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 14:06:14 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:07:15 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:07:53 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:08:37 ON 06 FEB 2008
               S L1

     FILE 'REGISTRY' ENTERED AT 14:18:42 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:18:44 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:18:51 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:19:17 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:20:08 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:21:14 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:21:17 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:25:03 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:28:54 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:29:00 ON 06 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:29:27 ON 06 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:31:26 ON 06 FEB 2008
L1             0 S 937.8.RID
L2             1 S PYRIDINE/CN
L3       1765430 S 46.156.30/RID
L4         14850 S 937.8/RID
L5           948 S L3 AND L4
L6             1 S CYCLOBUTANE/CN
L7        112681 S 4.209/RID
L8           186 S L5 AND L7

     FILE 'CAPLUS' ENTERED AT 14:35:28 ON 06 FEB 2008
L9             9 S L8

     FILE 'REGISTRY' ENTERED AT 14:35:42 ON 06 FEB 2008
L10           77 S L8 AND NRS=3
L11          185 S L8 AND CAPLUS/LC
L12            1 S L8 NOT L11

=> d
```

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 791586-43-1 REGISTRY
ED Entered STN: 02 Dec 2004
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)
MF C21 H22 N2 O5
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      13.68    1310.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -83.20

FILE 'CAPLUS' ENTERED AT 14:37:33 ON 06 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 6 Feb 2008  VOL 148 ISS 6
FILE LAST UPDATED: 5 Feb 2008  (20080205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d ibib abs hitstr l9 total
```

L9 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:653910 CAPLUS
DOCUMENT NUMBER: 147:226988
TITLE: GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models
AUTHOR(S): Medhurst, Andrew D.; Atkins, Alan R.; Beresford, Isabel J.; Brackenborough, Kim; Briggs, Michael A.; Calver, Andrew R.; Cilia, Jackie; Cluderay, Jane E.; Crook, Barry; Davis, John B.; Davis, Rebecca K.; Davis, Robert P.; Dawson, Lee A.; Foley, Andrew G.; Gartlon, Jane; Gonzalez, M. Isabel; Heslop, Teresa; Hirst, Warren D.; Jennings, Carol; Jones, Declan N. C.; Lacroix, Laurent P.; Martyn, Abbe; Ociepka, Sandrine; Ray, Alison; Regan, Ciaran M.; Roberts, Jennifer C.; Schogger, Joanne; Southam, Eric; Stean, Tania O.; Trail, Brenda K.; Upton, Neil; Wadsworth, Graham; Wald, Jeffrey A.; White, Trevor; Witherington, Jason; Woolley, Marie L.; Worby, Angela; Wilson, David M.
CORPORATE SOURCE: Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 321(3), 1032-1045
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 6[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) is a novel histamine H3 receptor antagonist with high affinity for human (pKi = 9.59-9.90) and rat (pKi = 8.51-9.17) H3 receptors. GSK189254 is >10,000-fold selective for human H3 receptors vs. other targets tested, and it exhibited potent functional antagonism (pA2 = 9.06 vs. agonist-induced changes in cAMP) and inverse agonism [pIC50 = 8.20 vs. basal guanosine 5'-O-(3-[35S]thio)triphosphate binding] at the human recombinant H3 receptor. In vitro autoradiog. demonstrated specific [3H]GSK189254 binding in rat and human brain areas, including cortex and hippocampus. In addition, dense H3 binding was detected in medial temporal cortex samples from severe cases of Alzheimer's disease, suggesting for the first time that H3 receptors are preserved in late-stage disease. After oral administration, GSK189254 inhibited cortical ex vivo R-(-)-α-methyl[imidazole-2,5(n)-3H]histamine dihydrochloride ([3H]R-α-methylhistamine) binding (ED50 = 0.17 mg/kg) and increased c-Fos immunoreactivity in prefrontal and somatosensory cortex (3 mg/kg). Microdialysis studies demonstrated that GSK189254 (0.3-3 mg/kg p.o.) increased the release of acetylcholine, noradrenaline, and dopamine in the anterior cingulate cortex and acetylcholine in the dorsal hippocampus. Functional antagonism of central H3 receptors was demonstrated by blockade of R-α-methylhistamine-induced dipsogenia in rats (ID50 = 0.03 mg/kg p.o.). GSK189254 significantly improved performance of rats in diverse cognition paradigms, including passive avoidance (1 and 3 mg/kg p.o.), water maze (1 and 3 mg/kg p.o.), object recognition (0.3 and 1 mg/kg p.o.), and attentional set shift (1 mg/kg p.o.). These data suggest that GSK189254 may have therapeutic potential for the symptomatic treatment of dementia in

Alzheimer's disease and other cognitive disorders.

IT 945493-87-8, GSK 189254
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclin. models)

RN 945493-87-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:678394 CAPLUS
DOCUMENT NUMBER: 145:124480
TITLE: Process for the preparation of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivatives as radio-labelled ligands for the human histamine H3 receptor
INVENTOR(S): Plisson, Christophe
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072596	A1	20060713	WO 2006-EP112	20060105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2594383	A1	20060713	CA 2006-2594383	20060105
EP 1836171	A1	20070926	EP 2006-700405	20060105
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				

PRIORITY APPLN. INFO.:
GB 2005-283 A 20050107
GB 2005-592 A 20050112
WO 2006-EP112 W 20060105

OTHER SOURCE(S): CASREACT 145:124480; MARPAT 145:124480
GI



I

AB Isotopomers of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-

yloxy)nicotinamide derivs. [I; R1 = a radio-labeled group and X = CO, or R1 = C2-6 alkyl and X = 11C; e.g., (11C-N-methyl)-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)nicotamide] are prepared which demonstrate a high binding affinity to the human histamine H3 receptor (e.g., pKi = 9.59) and are useful for the labeling and diagnostic imaging (e.g., PET scans) of human histamine H3 receptors.

IT 720690-56-2 720691-59-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(in a process for the preparation of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. as radio-labeled ligands for the human histamine H3 receptor)

RN 720690-56-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-59-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



IT 836611-32-6P 897928-06-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. as radio-labeled ligands for the human histamine H3 receptor)

RN 836611-32-6 CAPLUS
CN 3-Pyridinecarboxamide-11C, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 897928-06-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(methyl-11C)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:164593 CAPLUS
DOCUMENT NUMBER: 144:232933
TITLE: Preparation of tetrahydrobenzazepines as histamine H3 antagonists and/or reverse agonists.
INVENTOR(S): Parr, Christopher Allan; Pickering, Paula Louise; Sehmi, Sanjeet Singh; Wilson, David Matthew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018260	A1	20060223	WO 2005-EP8841	20050812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1778643	A1	20070502	EP 2005-771678	20050812
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
US 2007208005	A1	20070906	US 2007-573732	20070215
PRIORITY APPLN. INFO.:			GB 2004-18267 A	20040816
			WO 2005-EP8841 W	20050812

OTHER SOURCE(S): MARPAT 144:232933
GI



I

AB Title compds. [I; R1 = alkyl, cycloalkyl, alkylcycloalkyl; R2 = (substituted) aryl, heteroaryl, cycloalkylcycloalkyl, cycloalkylaryl, etc.; R3 = halo, alkyl, alkoxy, cyano, amino, CF3; n = 0-2; A = bond, O, S, imino], were prepared Thus, 4-(2,3,4,5-tetrahydro-1H-benzazepin-7-ylmethyl)benzonitrile (preparation given) was stirred 1 h with cyclobutanone in CH2Cl2/HOAc; NaBH(OAc)3 was added followed by stirring for 3 h to give 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]benzonitrile. The latter and addnl. I showed fpKi >9.5 in a histamine H3 functional antagonist assay.

IT 876517-80-5P 876517-81-6P 876517-82-7P
876517-88-3P 876517-90-7P 876517-92-9P
876518-03-5P 876518-04-6P 876518-06-8P
876518-17-1P 876518-18-2P 876518-19-3P
876518-20-6P 876518-21-7P 876518-22-8P
876518-23-9P 876518-31-9P 876518-32-0P
876518-33-1P 876518-34-2P 876518-35-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydrobenzazepines as histamine H3 antagonists and/or reverse agonists)

RN 876517-80-5 CAPLUS
CN 1H-3-Benzazepine, 7-[(5-bromo-2-pyridinyl)methyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 876517-81-6 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-3-pyridinyl]- (CA INDEX NAME)



RN 876517-82-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)



RN 876517-88-3 CAPLUS
CN 2-Pyridinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876517-90-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[6-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 876517-92-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]methyl]- (CA INDEX NAME)



RN 876518-03-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)



RN 876518-04-6 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-06-8 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 876518-17-1 CAPLUS
CN 1H-3-Benzazepine, 7-[(6-bromo-3-pyridinyl)methyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 876518-18-2 CAPLUS
CN 2-Oxazolidinone, 3-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 876518-19-3 CAPLUS
CN 2-Imidazolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]-3-methyl- (CA INDEX NAME)



RN 876518-20-6 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-21-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)



RN 876518-22-8 CAPLUS
CN Pyrrolidine, 1-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 876518-23-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-31-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-32-0 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 876518-33-1 CAPLUS
CN Pyrrolidine, 1-[[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 876518-34-2 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 876518-35-3 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-cyanophenyl)-5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



IT 876518-68-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydrobenzazepines as histamine H3 antagonists and/or reverse agonists)
RN 876518-68-2 CAPLUS
CN 1H-3-Benzazepine-7-acetonitrile, α-(5-bromo-2-pyridinyl)-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1354902 CAPLUS
DOCUMENT NUMBER: 144:69750
TITLE: Preparation of 3-cycloalkylbenzazepine derivatives as histamine H3 antagonists for treatment of neurological disease
INVENTOR(S): Bamford, Mark James; Pickering, Paula Louise; Wilson, David Matthew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123723	A1	20051229	WO 2005-EP6861	20050616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1756094	A1	20070228	EP 2005-755373	20050616
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2008502644	T	20080131	JP 2007-515905	20050616
US 2007232590	A1	20071004	US 2006-570383	20061211

PRIORITY APPLN. INFO.:

GB 2004-13757	A	20040618
GB 2004-13758	A	20040618
GB 2004-13763	A	20040618
GB 2004-13764	A	20040618
GB 2004-13765	A	20040618
GB 2004-13766	A	20040618
GB 2004-13768	A	20040618
GB 2004-13769	A	20040618
GB 2004-13770	A	20040618
WO 2005-EP6861	W	20050616

OTHER SOURCE(S): CASREACT 144:69750; MARPAT 144:69750
GI



I II

AB The title benzazepine derivs. I [wherein R = cycloalkyl; Ar = (un)substituted aryl or heteroaryl] or pharmaceutically acceptable salts thereof were prepared as histamine H3 antagonists for treatment of neurol. disease. For example, the compound II was prepared in a multi-step synthesis in good yield. II showed antagonistic activity with fPKi of 10.1 against histamine H3.

IT 871737-44-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)

RN 871737-44-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1126686 CAPLUS
DOCUMENT NUMBER: 143:386938
TITLE: Preparation of tertrahydrobenzazepines as histamine H3 and H1 receptor ligands
INVENTOR(S): Heightman, Thomas Daniel; Wilson, David Matthew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097778	A1	20051020	WO 2005-GB1333	20050406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735299	A1	20061227	EP 2005-732871	20050406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007532523	T	20071115	JP 2007-506834	20050406
US 2008009479	A1	20080110	US 2006-599636	20061004
PRIORITY APPLN. INFO.:			GB 2004-8083 A	20040408
			WO 2005-GB1333 W	20050406

OTHER SOURCE(S): MARPAT 143:386938
GI



I



II



III

AB Title compds. I [wherein R1 = (un)substituted alkyl; R2 = (un)substituted alkyl, aryl, etc.; R3 = halo, alkyl, alkoxy, cyano, amino or CF3; n = 0-2, or pharmaceutically acceptable salts thereof] were prepared as ligands of histamine receptors, especially histamine H3 receptors. For instance, 2,5-dichloropyrazine, which was obtained from aminopyrazine in two steps, underwent successive substitution with phenol II and 2-pyrrolidinone followed by deprotection with TFA. The resultant amine was reductively alkylated with cyclopropanecarboxaldehyde in the presence of sodium triacetoxyborohydride and catalytic amount of HOAc to give III. This compound exhibited antagonism >9 pKb and < 6.5 pKb in the histamine H3 and H1 functional antagonist assays, resp. Therefore, I and their pharmaceutical compns. are useful in the treatment of neurol. and psychiatric disorders (no data).

IT 866939-35-7P, 1-[6-[[3-(Cyclobutylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ligand; preparation of tertrahydrobenzazepines as histamine H1 and H3 receptor ligands)

RN 866939-35-7 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[[3-(cyclobutylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1021741 CAPLUS
DOCUMENT NUMBER: 143:326234
TITLE: Preparation of benzazepine derivatives as antagonists of histamine H1 and H3
INVENTOR(S): Bamford, Mark James; Heightman, Thomas Daniel; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005087746	A1	20050922	WO 2005-GB939		20050310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1730114	A1	20061213	EP 2005-718000		20050310
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV					
JP 2007528887	T	20071018	JP 2007-502403		20050310
US 2007185089	A1	20070809	US 2006-598759		20060911
PRIORITY APPLN. INFO.:			GB 2004-5628	A	20040312
			WO 2005-GB939	W	20050310

OTHER SOURCE(S): MARPAT 143:326234
GI



I



II

AB Title compds. I [R1 = (un)substituted cycloalkyl; R2 = aryl, heteroaryl, heterocycle, etc.; R3 = H, alkoxy, CN, etc.; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of histamine H1 and H3. Thus, e.g., II was prepared by coupling of 3-cyclobutyl-7-(1-piperazinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (preparation given) with 3-bromobenzonitrile. The activity of I was evaluated in the histamine H3 functional antagonist assay and selected compds. of the invention displayed a pKb in the range of >6.5 and >9.0. I as antagonists of histamine H1 and H3 should prove useful in the treatment of neurol. diseases. Pharmaceutical compns. comprising I are disclosed.

IT 865111-59-7P 865111-60-0P 865111-63-3P
865111-64-4P 865111-65-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 865111-59-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, methyl ester (CA INDEX NAME)



RN 865111-60-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 865111-63-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 865111-64-4 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 865111-65-5 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[1-(5-iodo-2-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)



IT 865107-95-5P 865110-91-4P 865110-93-6P
865111-05-3P 865111-09-7P 865111-19-9P
865111-22-4P 865111-23-5P 865111-27-9P
865111-28-0P 865111-29-1P 865111-32-6P
865111-34-8P 865111-35-9P 865111-36-0P
865111-51-9P 865111-52-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 865107-95-5 CAPLUS
CN Piperazine, 1-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-(3-pyridinyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 865110-91-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl- (CA INDEX NAME)



RN 865110-93-6 CAPLUS
CN Morpholine, 4-[[6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 865111-05-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenoxy]-N-methyl- (CA INDEX NAME)



RN 865111-09-7 CAPLUS
CN Piperidine, 1-[(6-cyano-3-pyridinyl)carbonyl]-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 865111-19-9 CAPLUS
CN Piperidine, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-[[6-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 865111-22-4 CAPLUS
CN Piperidine, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 865111-23-5 CAPLUS
CN Piperidine, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 865111-27-9 CAPLUS
CN Piperidine, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-[(6-methyl-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 865111-28-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[1-(6-methyl-3-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)



RN 865111-29-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[1-[6-(trifluoromethyl)-3-pyridinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 865111-32-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 865111-34-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 865111-35-9 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-3-pyridinyl]- (CA INDEX NAME)



RN 865111-36-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-pyridinyl)- (CA INDEX NAME)



RN 865111-51-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(6-cyano-3-pyridinyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 865111-52-0 CAPLUS
CN Benzamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-3-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:564644 CAPLUS
DOCUMENT NUMBER: 143:97280
TITLE: Preparation of benzazepine derivatives as histamine H3 antagonists
INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Dean, David Kenneth; Pickering, Paula Louise; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005058837	A1	20050630	WO 2004-EP14380		20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1713778	A1	20061025	EP 2004-803989		20041215
EP 1713778	B1	20080116			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS					
JP 2007514690	T	20070607	JP 2006-544347		20041215
US 2007060566	A1	20070315	US 2006-596503		20060615
PRIORITY APPLN. INFO.:			GB 2003-29214	A	20031217
			WO 2004-EP14380	W	20041215

OTHER SOURCE(S): CASREACT 143:97280; MARPAT 143:97280
GI



I



II

AB Title compds. I [R1 = (un)substituted cycloalkyl; R2 = H, alkyl, cycloalkyl, etc.; X = a bond, CO, CO2, etc.; R3 = halo, alkoxy, CN, etc.; R4 = H, aryl, heteroaryl, etc.; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of histamine H3. Thus, e.g., II was prepared by reductive amination of N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-morpholinecarboxamide (preparation given) with cyclobutanone. The activity of I was evaluated in the histamine H3 functional antagonist assay and it was revealed that numerous compds. of the invention possessed antagonism > 6.5 pKb. I as histamine H3 antagonists should prove useful in the treatment of neurol. disorders. Pharmaceutical compns. comprising I are disclosed.

IT 856901-13-8P 856902-29-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzazepine derivs. as histamine H3 antagonists)

RN 856901-13-8 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyridinyl)- (CA INDEX NAME)



RN 856902-29-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



IT 856901-12-7P 856901-17-2P 856901-40-1P
856901-42-3P 856901-43-4P 856901-44-5P
856901-45-6P 856901-46-7P 856901-47-8P
856901-49-0P 856901-50-3P 856901-63-8P
856901-66-1P 856901-67-2P 856901-83-2P
856901-84-3P 856901-85-4P 856901-86-5P
856901-89-8P 856902-03-9P 856902-04-0P
856902-05-1P 856902-06-2P 856902-07-3P
856902-08-4P 856902-09-5P 856902-10-8P
856902-11-9P 856902-12-0P 856902-13-1P
856902-14-2P 856902-15-3P 856902-16-4P
856902-24-4P 856902-30-2P 856902-32-4P
856902-34-6P 856902-43-7P 856902-44-8P
856902-51-7P 856902-59-5P 856902-60-8P
856902-76-6P 856902-77-7P 856902-82-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzazepine derivs. as histamine H3 antagonists)

RN 856901-12-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-N-methyl- (CA INDEX NAME)



RN 856901-17-2 CAPLUS
CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-pyridinyl)- (CA INDEX NAME)



RN 856901-40-1 CAPLUS
CN Benzamide, 4-(6-cyano-3-pyridinyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-

benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-42-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-methyl- (CA INDEX NAME)



RN 856901-43-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-methyl- (CA INDEX NAME)



RN 856901-44-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-45-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 856901-46-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 856901-47-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(trifluoromethyl)- (CA INDEX NAME)



RN 856901-49-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(3-pyridinyl)- (CA INDEX NAME)



RN 856901-50-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(4-morpholinyl)- (CA INDEX NAME)



RN 856901-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-66-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)



RN 856901-67-2 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methyl- (CA INDEX NAME)



RN 856901-83-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)



RN 856901-84-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-phenyl- (CA INDEX NAME)



RN 856901-85-4 CAPLUS
CN [3,3'-Bipyridine]-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-86-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 856901-89-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 856902-03-9 CAPLUS
CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-pyridinyl)- (CA INDEX NAME)



RN 856902-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-05-1 CAPLUS
CN [2,3'-Bipyridine]-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-06-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(5-pyrimidinyl)- (CA INDEX NAME)



RN 856902-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-08-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 856902-09-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-10-8 CAPLUS
CN [3,3'-Bipyridine]-6-carboxamide, 6'-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-11-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(5-pyrimidinyl)- (CA INDEX NAME)



RN 856902-12-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-pyrazinyl- (9CI) (CA INDEX NAME)



RN 856902-13-1 CAPLUS
CN [2,3'-Bipyridine]-6'-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-14-2 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 856902-15-3 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 856902-16-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)



RN 856902-24-4 CAPLUS
CN 4-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 856902-32-4 CAPLUS
CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl-4-(2-pyridinyl)- (CA INDEX NAME)



RN 856902-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N,6-dimethyl- (CA INDEX NAME)



RN 856902-43-7 CAPLUS
CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-3-pyridinyl- (CA INDEX NAME)



RN 856902-44-8 CAPLUS
CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-4-pyridinyl- (CA INDEX NAME)



RN 856902-51-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(5-cyano-2-pyridinyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-59-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyridinyl)- (CA INDEX NAME)



RN 856902-60-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-pyridinyl)- (CA INDEX NAME)



RN 856902-76-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyridinyloxy)- (CA INDEX NAME)



RN 856902-77-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-pyridinyloxy)- (CA INDEX NAME)



RN 856902-82-4 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-3-pyridinyl]- (CA INDEX NAME)



IT 856905-17-4P 856905-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzazepine derivs. as histamine H3 antagonists)
RN 856905-17-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856905-18-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-bromo-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:140980 CAPLUS
DOCUMENT NUMBER: 142:204628
TITLE: Radiolabeled imaging agents
INVENTOR(S): Bender, Dirk; Aburel, Pompiliu Sorin
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014479	A2	20050217	WO 2004-EP8830	20040805
WO 2005014479	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536659	A1	20050217	CA 2004-2536659	20040805
EP 1663868	A2	20060607	EP 2004-763865	20040805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007501764	T	20070201	JP 2006-522964	20040805
US 2007059230	A1	20070315	US 2006-567524	20061012
PRIORITY APPLN. INFO.:			GB 2003-18728 A	20030808
			GB 2004-16141 A	20040719
			WO 2004-EP8830 W	20040805

AB A novel process for preparing radiolabeled compds. by incorporation of radioactive carbonyl groups into precursors, which are then used to make the radiolabeled compds. These radiolabeled compds. have a number of uses including in vivo imaging techniques such as positron emission tomog. [11C]-Borane carbonyl is used as the labeled agent.

IT 836611-32-6P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
([11C]-borane carbonyl in preparation of radiopharmaceuticals)

RN 836611-32-6 CAPLUS

CN 3-Pyridinecarboxamide-11C, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)



IT 720691-59-8
RL: RCT (Reactant); RACT (Reactant or reagent)
([11C]-borane carbonyl in preparation of radiopharmaceuticals)
RN 720691-59-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



L9 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:546416 CAPLUS
DOCUMENT NUMBER: 141:106391
TITLE: Preparation of benzo[d]azepine derivatives as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurological disorders
INVENTOR(S): Bamford, Mark James; Dean, David Kenneth; Sehmi, Sanjeet Singh; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056369	A1	20040708	WO 2003-EP14556	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509413	A1	20040708	CA 2003-2509413	20031218
AU 2003294909	A1	20040714	AU 2003-294909	20031218
AU 2003294909	B2	20070517		
EP 1572215	A1	20050914	EP 2003-785885	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017483	A	20051116	BR 2003-17483	20031218
CN 1726042	A	20060125	CN 2003-80106364	20031218
JP 2006512412	T	20060413	JP 2005-502553	20031218
NZ 540148	A	20071130	NZ 2003-540148	20031218
ZA 2005004270	A	20060726	ZA 2005-4270	20050525
IN 2005DN02232	A	20070105	IN 2005-DN2232	20050526
US 2006040918	A1	20060223	US 2005-539385	20050616
MX 2005PA06567	A	20050816	MX 2005-PA6567	20050617
KR 765027	B1	20071009	KR 2005-711441	20050617
NO 2005003384	A	20050915	NO 2005-3384	20050712
US 2007299056	A1	20071227	US 2007-831191	20070731
KR 2007089762	A	20070831	KR 2007-719049	20070820

PRIORITY APPLN. INFO.:	GB 2002-29820	A	20021220
	GB 2003-12607	A	20030602
	WO 2003-EP14556	W	20031218
	US 2005-539385	A3	20050616
	KR 2005-711441	A3	20050617

OTHER SOURCE(S): MARPAT 141:106391
GI



I

AB The title compds. [I; R1 = cycloalkyl optionally substituted by alkyl; R2 = H, alkyl, X(cycloalkyl), X(aryl), etc.; X = a bond, alkyl; R3 = halo, alkyl, alkoxy, CN, NH2, CF3; n = 0-2], useful in the treatment of neurol. and psychiatric disorders, were prepared Thus, reacting 7-benzyloxy-1,2,4,5-tetrahydrobenzo[d]azepine (preparation given) with cyclobutanone in the presence of NaBH(OAc)3 afforded I [R1 = cyclobutyl; R2 = CH2Ph; n = 0] which showed pKb of 9.0-10.5 in the histamine H3 functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.

IT 720691-59-8P 720691-60-1P 720691-66-7P
720691-83-8P 720691-84-9P 720691-88-3P
720693-38-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720691-59-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 720691-60-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 720691-66-7 CAPLUS

CN Ethanone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-83-8 CAPLUS
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 720691-84-9 CAPLUS
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, disodium salt (9CI) (CA INDEX NAME)



RN 720691-88-3 CAPLUS
CN 3-Pyridinamine, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720693-38-9 CAPLUS
CN 2-Pyridinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



IT 720689-73-6P 720689-84-9P 720690-34-6P
720690-35-7P 720690-36-8P 720690-52-8P
720690-53-9P 720690-54-0P 720690-55-1P
720690-56-2P 720690-57-3P 720690-58-4P
720690-59-5P 720690-60-8P 720690-61-9P
720690-62-0P 720690-63-1P 720690-64-2P
720690-65-3P 720690-66-4P 720690-67-5P
720690-68-6P 720690-69-7P 720690-73-3P
720691-13-4P 720691-14-5P 720691-15-6P
720691-16-7P 720691-17-8P 720691-18-9P
720691-40-7P 720691-41-8P 720691-42-9P
720691-43-0P 720691-44-1P 720691-45-2P
720691-46-3P 720691-47-4P 720691-48-5P
720691-49-6P 720691-50-9P 720691-51-0P
720691-52-1P 720691-53-2P 720691-54-3P
720691-55-4P 720691-58-7P 720691-61-2P
720691-65-6P 720691-67-8P 720691-68-9P
720691-69-0P 720691-70-3P 720691-71-4P
720691-72-5P 720691-73-6P 720691-74-7P
720691-77-0P 720691-89-4P 720691-90-7P
720691-91-8P 720691-92-9P 720691-93-0P
720691-94-1P 720691-97-4P 720691-98-5P
720692-00-2P 720692-01-3P 720692-02-4P
720692-03-5P 720692-04-6P 720692-13-7P
720692-14-8P 720692-31-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720689-73-6 CAPLUS
CN Piperidine, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 720689-84-9 CAPLUS
CN Piperidine, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-34-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyridinylmethoxy)-
(CA INDEX NAME)



RN 720690-35-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(3-pyridinylmethoxy)-
(CA INDEX NAME)



RN 720690-36-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-pyridinylmethoxy)-
(CA INDEX NAME)



RN 720690-52-8 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-
benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720690-53-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyridinyloxy)- (CA INDEX NAME)



RN 720690-54-0 CAPLUS
CN Morpholine, 4-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-55-1 CAPLUS
CN Pyrrolidine, 1-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-56-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720690-57-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 720690-58-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720690-59-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopentyl- (CA INDEX NAME)



RN 720690-60-8 CAPLUS
CN Piperidine, 1-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-61-9 CAPLUS
CN Piperidine, 1-[[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-62-0 CAPLUS
CN Pyrrolidine, 1-[[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-63-1 CAPLUS
CN Morpholine, 4-[[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-64-2 CAPLUS
CN Piperidine, 1-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-65-3 CAPLUS
CN Thiomorpholine, 4-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 720690-66-4 CAPLUS
CN Pyrrolidine, 1-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-67-5 CAPLUS
CN Morpholine, 4-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-68-6 CAPLUS
CN Morpholine, 4-[[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-69-7 CAPLUS
CN Piperidine, 1-[[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-13-4 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720691-14-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 720691-15-6 CAPLUS
CN Azetidine, 1-[[6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720691-16-7 CAPLUS
CN Morpholine, 4-[[6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720691-17-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 720691-18-9 CAPLUS
CN 4-Pyridinecarbonitrile, 2-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720691-40-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-41-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)



RN 720691-42-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720691-43-0 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720691-44-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-45-2 CAPLUS
CN Pyrrolidine, 1-[[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720691-46-3 CAPLUS
CN Morpholine, 4-[[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720691-47-4 CAPLUS
CN 1,4-Oxazepine, 4-[[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]carbonyl]hexahydro- (9CI) (CA INDEX NAME)



RN 720691-48-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopentyl- (CA INDEX NAME)



RN 720691-49-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopropyl- (CA INDEX NAME)



RN 720691-50-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 720691-51-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-

7-yl)oxy]-N-ethyl- (CA INDEX NAME)



RN 720691-52-1 CAPLUS
CN 3-Pyridinecarboxamide, N-cyclobutyl-6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-53-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720691-54-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720691-55-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-58-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(3-pyridinyloxy)- (CA INDEX NAME)



RN 720691-61-2 CAPLUS
CN Acetamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-65-6 CAPLUS
CN 2(1H)-Pyridinone, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-67-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(1H-pyrazol-3-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-68-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-69-0 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-70-3 CAPLUS
CN 2-Piperidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-71-4 CAPLUS
CN 2-Azetidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-72-5 CAPLUS
CN 2-Oxazolidinone, 3-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-73-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(1H-pyrazol-1-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-74-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(3,5-dimethyl-4-isoxazolyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-77-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-8-iodo-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-89-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-90-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-91-8 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-92-9 CAPLUS
CN Propanamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-2-methyl- (CA INDEX NAME)



RN 720691-93-0 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]tetrahydro- (CA INDEX NAME)



RN 720691-94-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(4,6-dimethoxy-2-pyrimidinyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-97-4 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[(3,5-dimethyl-2-pyridinyl)oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-98-5 CAPLUS
CN Morpholine, 4-[[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 720692-00-2 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-ethoxy- (CA INDEX NAME)



RN 720692-01-3 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-methyl- (CA INDEX NAME)



RN 720692-02-4 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-5-methyl- (CA INDEX NAME)



RN 720692-03-5 CAPLUS
CN 2-Imidazolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-3-methyl- (CA INDEX NAME)



RN 720692-04-6 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-hydroxy-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720692-13-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(1,1-dioxido-2-isothiazolidinyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-14-8 CAPLUS
CN 2-Imidazolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720692-31-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



IT 720692-58-0P 720692-59-1P 720692-70-6P
720692-71-7P 720692-72-8P 720692-74-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)
RN 720692-58-0 CAPLUS
CN 2-Propen-1-one, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-3-(dimethylamino)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 720692-59-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, hydrazide (CA INDEX NAME)



RN 720692-70-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-71-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, methyl ester (CA INDEX NAME)



RN 720692-72-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-74-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(6-methoxy-3-pyridinyl)oxy]- (CA INDEX NAME)



=>